# iHeart Japan Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iheart-japan

- Industry: Pharmaceuticals
- Headquarters: Kyoto, Japan
- Website: www.iheartjapan.jp
- Total disclosed funding: $5.5M
- Latest round: Series D (Sep 1, 2025)
- Investors on record: 1

## About

iHeart Japan is a Japan-based medical research company focused on developing regenerative medical products, specifically utilizing induced pluripotent stem (iPS) cells, to provide innovative treatment solutions for heart conditions.Founded in 2013 and headquartered in Kyoto, Japan, iHeart Japan Corporation specializes in regenerative medicine and has adapted its strategies over time to enhance its operational focus. The company has completed a total of 3 deals, with the most recent deal occurring on July 7, 2021, when they raised JPY 800 million in venture funding, representing the total amount raised to date. The founder's details are not publicly available.iHeart Japan???? specializes in developing regenerative medical products, particularly utilizing induced pluripotent stem (iPS) cells. The company provides innovative treatment options for critical heart conditions through cellular therapies aimed at improving cardiac health. Their products are designed for hospitals, medical research institutions, and healthcare providers focusing on regenerative medicine, and they serve markets both within Japan and internationally.iHeart Japan???? operates through partnerships with healthcare institutions and medical research organizations, generating revenue from the sale of regenerative medical products. Their business model includes B2B transactions with hospitals and clinics as well as agreements for bulk purchasing or subscription services for iPS cell-derived therapies. Pricing structures reflect the advanced nature of their treatments, aligning with industry standards for regenerative therapies.With the recent funding round on July 7, 2021, where iHeart Japan raised JPY 800 million, the company is set to proceed with clinical trials for IHJ-301. iHeart Japan plans to enhance its product offerings, particularly focusing on the launch of new regenerative medical products and expanding its operations into international markets where there is a demand for advanced therapies.

## Funding rounds

- Series D, Sep 1, 2025, $5.5M — Mitsui Sumitomo Insurance Venture Capital

## Investors

- Mitsui Sumitomo Insurance Venture Capital (https://capitalatlas.ai/funds/mitsui-sumitomo-insurance-venture-capital) — Series D